Adverse effects of ATG/ALG treatment in aplastic anemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-center cohort will enroll 200 patients with aplastic anemia who are receiving ATG or ALG as their first immunosuppressive therapy. Investigators will systematically record and describe clinical adverse reactions during and after treatment, including timing, severity, and management. Patients who have had a prior hematopoietic stem cell transplant or who receive ATG/ALG only as transplant conditioning are excluded. The collected data are intended to provide a foundation for developing targeted strategies to prevent and treat treatment-related complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Meet the diagnostic criteria for aplastic anemia (Camitta criteria);
* Receiving ATG/ALG immunosuppressive therapy for the first time;

Exclusion Criteria:

* Previously received hematopoietic stem cell transplantation;
* Aplastic anemia patients receiving ATG/ALG as part of transplant conditioning regimen;

Where it's running

• Regenerative Medicine Center and Red Blood Cell Disorders Center
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Weiwang Li, PhD
• Email: liweiwang@ihcams.ac.cn
• Phone: 15332132036

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BFCA conditioning for Haplo-HSCT in older adults with severe aplastic anemia

  This study tests the BFCA conditioning regimen in adults aged 40–60 with severe aplastic anemia undergoing haploidentical stem cell transplant to see if it’s safe and effective.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07586735

• Haplo‑cord versus haplo hematopoietic stem cell transplant for aplastic anemia

  This trial will test whether adding unrelated cord blood to a haploidentical stem cell transplant (haplo‑cord) helps people aged 14 and older with aplastic anemia more than a haploidentical transplant alone.

  Recruiting at 4 sites The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu and 3 other locations · NCT07499284

• Sirolimus with or without cyclosporin A for Chinese adults with aplastic anemia who are refractory or intolerant to CsA

  This trial will test whether adding cyclosporin A to sirolimus helps Chinese adults with aplastic anemia who did not respond to or could not tolerate cyclosporin A.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06802055

• Lower-dose immunosuppression plus hetrombopag for severe aplastic anemia in people 65 and older

  This study tests whether a lower-dose immunosuppressive regimen combined with hetrombopag can improve blood counts and safety for people aged 65 and older with severe or very severe aplastic anemia.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07010237

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.